Cellular Biomedicine Group (CBMG) to Present at the 19th BIO CEO & Investor Conference on February 13, 2017
February 07 2017 - 8:31AM
Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the
“Company”), a clinical-stage biopharmaceutical firm engaged in
the development of effective immunotherapies for cancer and stem
cell therapies for degenerative diseases, today announced that Tony
(Bizuo) Liu, Chief Executive Officer of the Company, will present
at the 19th Annual BIO CEO & Investor Conference on
Monday, February 13, 2017, at 9:30 a.m. Eastern Time, at the
Waldorf Astoria Hotel in New York City.
A live audio webcast of the presentation will be
available on the company's website
at http://www.cellbiomedgroup.com/investor-relations/presentations/.
Webcast replay will be available one hour after conclusion of the
live event.
About Cellular Biomedicine Group
(CBMG)Cellular Biomedicine Group, Inc. develops
proprietary cell therapies for the treatment of cancer and
degenerative diseases. Our immuno-oncology and stem cell projects
are the result of research and development by CBMG’s scientists and
clinicians from both China and the United States. Our GMP
facilities in China, consisting of twelve independent cell
production lines, are designed and managed according to both China
and U.S. GMP standards. To learn more about CBMG, please visit:
www.cellbiomedgroup.com
Forward-Looking
StatementsStatements in this press release relating to
plans, strategies, trends, specific activities or investments, and
other statements that are not descriptions of historical facts may
be forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include risks
inherent in doing business, trends affecting the global economy,
including the devaluation of the RMB by China in August 2015 and
other risks detailed from time to time in CBMG’s reports filed with
the Securities and Exchange Commission, quarterly reports on form
10-Q, current reports on form 8-K and annual reports on form 10-K.
Forward-looking statements may be identified by terms such as
"may," "will," "expects," "plans," "intends," "estimates,"
"potential," or "continue," or similar terms or the negative of
these terms. Although CBMG believes the expectations reflected in
the forward-looking statements are reasonable, they cannot
guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to
update these forward-looking statements other than as required by
law.
Contacts:
Sarah Kelly
Director of Corporate Communications, CBMG
+1 408-973-7884
sarah.kelly@cellbiomedgroup.com
Vivian Chen
Managing Director Investor Relations
+1 347 481-3711
vivian.chen@citigatedr.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Sep 2023 to Sep 2024